Google DeepMind has transitioned its next-generation model, Gemini 4, into the early post-training phase. Koray Kavukcuoglu, elevated to Senior Vice President of Google DeepMind on August 12, 2026, ...
Barapullah Phase 3, a 3.5-km elevated corridor linking Mayur Vihar Phase I and Sarai Kale Khan, is expected to open on September 29, cutting travel time and improving connectivity between East Delhi, ...
U.S. Customs and Border Protection (“CPB”) has notified the Court of International Trade (“CIT”) that Phase 3 of its Consolidated Administration and Processing of Entries (“CAPE”) will deploy on ...
BARCELONA—AstraZeneca AZN0.89%increase; up pointing triangle said its new drug for chronic obstructive pulmonary disease showed benefits across a broad patient population in late-stage clinical trials ...
Pelacarsen lowered lipoprotein(a) by up to 80 percent in Phase 2, and that number turned out to mean almost nothing for what patients actually care about. Novartis announced September 4 that the ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes ...
With the last patient’s 72-week visit now complete in the NATiV3 Phase 3 trial, Inventiva is roughly one data-lock away from knowing whether lanifibranor can challenge a MASH treatment landscape that ...
Different stages of melanoma have a higher risk of the skin cancer coming back after being surgically removed. An experimental therapy developed by Merck and Moderna aims to help lower the recurrence ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine—individually tailored to target a patient’s unique cancer mutations—was effective in a late-stage ...
FDA concurrence on protocol elements reduces registrational risk by confirming population, duration, dose, endpoint hierarchy, and statistical plan ahead of the pivotal Phase 3 program. UMSARS Part I ...
Licensure was supported by phase 3 efficacy in adults 50–64 years and positioned as a platform advance for older populations at higher influenza complication risk. Trial outcomes showed 26.6% relative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results